Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dyne TherapeuticsDYN +0.95%34 EV-to-OCF is -8.94 as of Aug. 10, 2026. GuruFocus rates DYN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, Dyne Therapeutics ranks better than 67.12% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Dyne Therapeutics's Enterprise Value is $4,269.50 Mil.
Dyne Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-477.82 Mil. Therefore, Dyne Therapeutics's EV-to-OCF for today is -8.94.
The historical rank and industry rank for Dyne Therapeutics's EV-to-OCF or its related term are showing as below:
DYN'
s EV-to-OCF Range Over the Past 10 Years
Min: -9.05 Med: 0 Max: -8.65
Current: -8.94
During the past 8 years, the highest EV-to-OCF of Dyne Therapeutics was -8.65. The lowest was -9.05. And the median was .
DYN's EV-to-OCF is ranked better than 67.12% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs DYN: -8.94
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dyne Therapeutics's PE Ratio (TTM) for today is calculated as:
Dyne Therapeutics's share price for today is $26.50.
Dyne Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Dyne Therapeutics EV-to-OCF Related Terms
Dyne Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Dyne Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dyne Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dyne Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Dyne Therapeutics's EV-to-OCF falls into.
Dyne Therapeutics's current Enterprise Value is $4,269.50 Mil.
Dyne Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-477.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dyne Therapeutics (DYN) has a EV-to-OCF of -8.94 as of Aug. 10, 2026. According to the industry distribution chart, Dyne Therapeutics ranks #462 out of 1405 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Dyne Therapeutics' EV-to-OCF too high?
Dyne Therapeutics' current EV-to-OCF is -8.94. Based on the distribution chart, Dyne Therapeutics ranks #462 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Dyne Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Dyne Therapeutics' EV-to-OCF compare to VKTX and CELC?
According to the Biotechnology industry distribution chart, Dyne Therapeutics ranks #462 out of 1405 companies for EV-to-OCF. This puts Dyne Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Dyne Therapeutics's current EV-to-OCF is -8.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyne Therapeutics stock overvalued right now?
Dyne Therapeutics (DYN) has a current EV-to-OCF of -8.94. The current EV-to-OCF is -8.94. Dyne Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Dyne Therapeutics (DYN), the current EV-to-OCF is -8.94 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
34GF Score
Get the complete analysis for DYN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYN has been successfully added to your 
